- Adagio Therapeutics ADGI has set terms for the IPO, looking to raise well north of $300 million if they hit the top of the $16 to $18 range.
- Since its inception in 2020, the Company has raised $470 million from some high-profile investors.
- At the midpoint, the valuation sits right around $2 billion.
- The Company earlier filed to raise $100 million via IPO.
- As per the S-1/A, the Company has earmarked approximately $545.0 million to fund clinical development, manufacturing supply, and initial commercialization costs for ADG20, its COVID-19 antibody candidate.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
